LINC01293: A Potential Drug Target and Biomarker (G101927861)

Target Name: LINC01293

NCBI ID: G101927861

LINC01293

Other Name(s): Long intergenic non-protein coding RNA 1293 | long intergenic non-protein coding RNA 1293

LINC01293: A Potential Drug Target and Biomarker

LINC01293 is a long intergenic non-protein coding RNA (lncRNA) molecule that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells throughout the body. The function of LINC01293 is not well understood, but its expression has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

One of the most promising aspects of LINC01293 is its potential as a drug target. The non-coding RNA molecule has been shown to play a role in the development and progression of a number of diseases, including cancer. LINC01293 has also been shown to interact with several protein molecules, including the oncogene transforming growth factor-??1 (NF-kappa1) and the transcription factor PDGF-??.

In addition to its potential as a drug target, LINC01293 has also been shown to be a potential biomarker for a number of diseases. The expression of LINC01293 has been associated with the development of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that LINC01293 may be a useful biomarker for these diseases.

Biomarker Potential

In addition to its potential as a drug target, LINC01293 has also been shown to be a potential biomarker for a number of diseases. The expression of LINC01293 has been associated with the development of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that LINC01293 may be a useful biomarker for these diseases.

For example, studies have shown that LINC01293 is highly expressed in cancer tissues and that its expression is associated with the development of cancer. In addition, studies have shown that LINC01293 is highly expressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that LINC01293 may be a useful biomarker for these diseases.

Furthermore, LINC01293 has also been shown to be highly expressed in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. This suggests that LINC01293 may be a useful biomarker for these diseases as well.

Conclusion

In conclusion, LINC01293 is a long intergenic non-protein coding RNA molecule that has been identified as a potential drug target and biomarker. Its expression has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the function of LINC01293 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1293

The "LINC01293 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01293 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets